8 analysts have shared their evaluations of Pfizer PFE during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 2 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $41.25, with a high estimate of $75.00 and a low estimate of $27.00. This upward trend is evident, with the current average reflecting a 12.49% increase from the previous average price target of $36.67.
Interpreting Analyst Ratings: A Closer Look
The standing of Pfizer among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | - |
| Steve Scala | TD Cowen | Announces | Market Perform | $32.00 | - |
| Robyn Karnauskas | Truist Securities | Lowers | Buy | $36.00 | $42.00 |
| Colin Bristow | UBS | Lowers | Neutral | $27.00 | $34.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $28.00 | $34.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $42.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $75.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pfizer. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pfizer compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Pfizer's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pfizer's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Pfizer analyst ratings.
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Unraveling the Financial Story of Pfizer
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Pfizer's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -41.55%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Pfizer's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -18.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pfizer's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.43%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.09%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Pfizer's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
